Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
3.95% $1.580
America/New_York / 27 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 340.03 mill |
EPS: | -0.570 |
P/E: | -2.77 |
Earnings Date: | Mar 06, 2024 |
SharesOutstanding: | 215.21 mill |
Avg Daily Volume: | 1.896 mill |
RATING 2024-03-27 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Strong Buy | |
P/E: | Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -2.77 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.47x |
Company: PE -2.77 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 1.410 - 1.750 ( +/- 10.76%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-08 | Ecor1 Capital, Llc | Buy | 0 | Ordinary Shares |
2024-03-18 | Piccina Cintia | Buy | 5 088 864 | Option to purchase Ordinary Shares |
2024-03-18 | Piccina Cintia | Buy | 1 130 832 | Option to purchase Ordinary Shares |
2024-01-17 | Rawcliffe Adrian | Sell | 30 080 | American Depositary Shares representing Ordinary Shares |
2024-01-16 | Rawcliffe Adrian | Sell | 9 304 | American Depositary Shares representing Ordinary Shares |
INSIDER POWER |
---|
96.18 |
Last 96 transactions |
Buy: 71 750 188 | Sell: 1 254 319 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $1.580 (3.95% ) |
Volume | 1.180 mill |
Avg. Vol. | 1.896 mill |
% of Avg. Vol | 62.25 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $1.140 | N/A | Active |
---|
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.